Fueled with a fresh half-billion dollars as AI investments boom, Exscientia is hitting the gas on drug development
Can AI revolutionize the way new drugs are found and developed? For Exscientia, that’s now the half-billion-dollar question.
It hasn’t been two months since Exscientia expanded its Series C round, but the decade-old machine learning outfit is already back at the venture well, this time pulling in up to $525 million for its AI platform and pipeline.
The raise includes a $252 Series D round, plus a $300 million equity investment by SoftBank that can be drawn at the company’s discretion. The SoftBank Vision Fund 2 led the Series D, with a hand from Novo Holdings, BlackRock, Mubadala Investment, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.